Page 6 - Device Agency News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K -December 18, 2023 at 07:02 am EST

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes SUNNYVALE, Calif. - December.

United statesPeter altmanMiranda petoDavid mcclungDevice agency consultation minutesMedicaid servicesExchange commission onBiocardia incDevice agencyCardiamp cell therapy programMaryland stem cell research fundCenters for medicareBiocardia announces expectedFailure japan approval timeline basedMedical device agency consultationJapan pharmaceutical

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

Peter altmanBiocardia cardiDevice agencyBiocardia incMedical device agencyFailure trialChief executive

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPeter altmanBiocardia cardiMiranda petoDavid mcclungExchange commission onBiocardia incCenters for medicareDevice agencyCardiamp cell therapy programMedicaid servicesMaryland stem cell research fundCardia shares updateCell therapyIschemic heart failureForeign data expected

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval - BioCardia (NASDAQ:BCDA)

SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an

United statesMiranda petoDavid mcclungBiocardia cardiPeter altmanCardiamp cell therapy programDevice agencyMaryland stem cell research fundBiocardia incExchange commission onMedicaid servicesCenters for medicareMedical device agencyFailure trialChief executiveCell therapy

BioCardia, Inc (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by and welcome to the BioCardia 2023 Third Quarter Conference Call. At this time, all participants are in a listen-only mode.

United statesPeter altmanJoe pantginisMiranda petoDavid mcclungJoe smithPeter altmansDevice agencyBiocardia incCall transcript novemberQuarter conferenceBiocardia investorChief executive officerChief financialData safety monitoring boardMinnesota living with heart failure questionnaire